drugset
drugset / Trial / NCT06467565

NALIRIFOX as Induction Therapy in LAPC

NCT06467565 ↗

Phase 2 Unknown 20 enrolled The First Affiliated Hospital with Nanjing Medical University
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, single arm, single center, phase II study of NALIRIFOX as conversion therapy in patients with locally advanced pancreatic cancer.

Timeline

Start
2023-12-25
Primary completion
2024-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject IRINOTECAN Small molecule 50 mg/m2 Intravenous

Indications

pancreatic ductal adenocarcinoma